Q4 Expands Presence and Customers in EMEA — Helping More Companies Improve Investor Relations Productivity and Results
Q4 Inc. (“Q4” or “the company”), the IR Ops Platform, today announced strong growth and momentum across Europe, the Middle East and Africa (EMEA) — significantly expanding its workforce and customers there. As more businesses in the region tap into the Q4 Platform for investor relations (IR), they’re able to boost efficiency, reduce program execution risks and vastly improve IR outcomes, including enhancing investor relationships and driving premium valuations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240917555274/en/
Tanya Thomas (Photo: Business Wire)
Q4 partners with EMEA businesses including The Adecco Group, Caledonia Mining, Compugen, Voxeljet and many more on the London Stock Exchange, Euronext, Nasdaq Nordic and SIX Swiss Exchange — as well as 2,600+ others around the world, including half of the S&P 500. They use Q4’s powerful, consolidated platform to address comprehensive IR needs: with solutions for IR websites, virtual events, an IR CRM, shareholder identification, engagement analytics and more, including secure AI for IR.
Over the last year, Q4 has heavily increased its customer base in EMEA, with substantial traction across the UK, Switzerland and Nordic countries. In addition, the company grew its own headcount in EMEA by 50% during that time period.
Announcing Q4’s EVP of EMEA
As Q4 continues its international growth, the company has appointed Tanya Thomas to play a key role in that effort: as Executive Vice President (EVP) of EMEA. Based in London, Thomas brings extensive leadership experience at global B2B technology companies: leading their rapid and highly successful geographic expansions, and building scalable revenue streams. In her role at Q4, Thomas will focus on further driving Q4’s strategic growth in EMEA and other international markets, and overseeing and executing on related operational activities.
Prior to Q4, Thomas served as Chief Growth Officer at OpenExchange, a provider of professionally managed virtual meetings and events in the capital markets. She was previously CEO of GDS Group, a digital transformation solutions provider, and Group Sales Director at UBM plc, a B2B events organizer acquired by Informa, among other roles.
“We see great opportunity for Q4 in EMEA, and as we continue the next phase of our strategic growth, Tanya will be a terrific asset to our business and customers alike,” said Darrell Heaps, CEO, Q4. “Tanya’s experience in capital markets and virtual events — combined with her history of successfully executing market and international expansions — make her an ideal addition to our team. As we help IR leaders and their businesses attract, manage and understand investors, we look forward to bringing the benefits of our platform to businesses on an even wider scale.”
Thomas and other members of Q4 will represent the company at upcoming regional events, including the Reputation Management & Corporate Comms Conference, in London, on Sept. 18, and DIRF 2024, in Copenhagen, Denmark, on Sept. 19, where Q4 is a premium conference sponsor.
“It’s an incredibly exciting time to join Q4 — with the company recently pioneering the industry’s first IR Ops Platform,” said Tanya Thomas, EVP of EMEA, Q4. “Listed companies in EMEA are showing great demand and excitement for the consolidated and AI-driven functionality Q4 provides. I’m looking forward to working with the talented team here to capitalize on this demand, extend our leadership in the region, and serve more customers with Q4’s proven and trusted solutions.”
About Q4 Inc.
Q4 Inc. is the first IR Ops Platform with the world’s largest set of proprietary investor data, purpose-built to remove obstacles between public companies and their investors. Q4 gives investor relations leaders and their teams the tools to attract, manage, and understand investors — all in one place. The AI-enabled Q4 IR Ops Platform boasts applications for website and event management, engagement analytics, and earnings lifecycle management, including AI Earnings Co-Pilot to generate draft scripts based on historical data, and AI earnings call summaries to understand peer sentiment. The Platform also includes a streamlined investor CRM and shareholder intelligence with enhanced metrics to elevate investor targeting strategies. Q4 delivers the data, insights, and workflows that give IR teams the power to focus on what really matters: strategy, relationships, and driving premium valuations for their companies.
The company is a trusted partner to more than 2,600 public companies globally, including many of the most respected brands in the world, and maintains an award winning culture where team members grow and thrive.
Q4 is headquartered in Toronto, with offices in London and Copenhagen. Learn more at www.q4inc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240917555274/en/
Contacts
Media:
Heather Noll
Director, Brand and Content Marketing
media@q4inc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom